Healthcare · NIFTY 500
Natco Pharma Limited
NSENATCOPHARM
BSE524816 ISININE987B01026 SeriesEQ Listed on NSE · BSE
₹808.80 -0.15 (-0.02%) Updated 12 Nov, 8:49 pm IST
Price, daily close-1.57% in a year
Today
- Open
- ₹809.90
- Prev close
- ₹808.95
- Day high
- ₹830.00
- Day low
- ₹806.55
- Volume
- 6.46 L
- Value traded
- ₹52.58 Cr
- Upper circuit
- ₹970.70
- Lower circuit
- ₹647.20
- 52W high
- ₹1,226.80
- 52W low
- ₹773.60
- 1 month
- +1.46%
- 6 months
- -33.08%
52W low52W high
Ratios
Key numbers
Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.
Market cap₹14,478 Cr
P/E (TTM)12.66
P/B1.57
Book value / share₹515.15
EPS (TTM)₹63.89
ROE12.4%
Dividend yield0.56%
Dividend (12m)₹4.50 / share
Net margin (TTM)32.8%
Operating margin25.4%
Debt / equity0.08
Current ratio3.01
EV / EBITDA14.24
Sales growth (YoY qtr)-44.68%
Profit growth (YoY qtr)-57.04%
Sales CAGR 3Y+14.64%
Profit CAGR 3Y+25.64%
Shares17.90 Cr
Quarterly results
Results for each quarter
Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.
Revenue and net profit
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Revenue · QoQ (vs last quarter)
—-26%+41%+28%+0.6%-65%+157%+8.8%+2.6%-53%+14%-0.5%
Revenue · YoY (vs a year ago)
————+33%-37%+14%-2.5%-0.6%+36%-39%-45%
Net profit · QoQ (vs last quarter)
—-42%+82%+73%+1.3%-80%+206%+18%+7.8%-71%+77%-23%
Net profit · YoY (vs a year ago)
————+84%-37%+5.3%-28%-23%+14%-34%-57%
RevenueNet profitLine = trend
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
EPS (₹) · YoY (vs a year ago)
————+84%-37%+5.3%-28%-23%+14%-34%-57%
EPS (₹)Line = trend
| ₹ Cr | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,031 | 759 | 1,068 | 1,363 | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 |
| Other income | 29.4 | 37.0 | 42.0 | 48.1 | 63.8 | 176 | 66.3 | 61.7 | 100 | 58.1 | 77.8 | 59.2 |
| Total income | 1,061 | 796 | 1,110 | 1,411 | 1,435 | 651 | 1,287 | 1,391 | 1,463 | 705 | 817 | 794 |
| Raw material | 167 | 92.2 | 128 | 151 | 143 | 72.7 | 169 | 181 | 175 | 135 | 103 | 158 |
| Purchases | 41.0 | 36.7 | 31.1 | 32.5 | 53.7 | 39.1 | 40.8 | 37.3 | 72.6 | 55.8 | 37.5 | 27.8 |
| Employee cost | 122 | 122 | 143 | 142 | 152 | 142 | 159 | 169 | 200 | 159 | 159 | 179 |
| Other expenses | 235 | 206 | 286 | 236 | 238 | 212 | 264 | 356 | 414 | 196 | 298 | 222 |
| Total expenses | 621 | 539 | 633 | 607 | 617 | 487 | 781 | 819 | 849 | 544 | 673 | 609 |
| Operating profit | 458 | 268 | 497 | 805 | 804 | 38.8 | 548 | 571 | 579 | 159 | 128 | 187 |
| OPM % | 44.4% | 35.3% | 46.6% | 59.1% | 58.7% | 8.2% | 44.9% | 43.0% | 42.5% | 24.5% | 17.3% | 25.4% |
| Finance cost | 4.2 | 4.6 | 6.2 | 5.2 | 4.1 | 4.4 | 10.2 | 3.2 | 13.1 | 9.5 | 10.9 | 13.0 |
| Depreciation | 43.6 | 44.2 | 55.5 | 44.1 | 45.8 | 47.0 | 98.3 | 57.6 | 52.4 | 46.2 | 50.4 | 47.1 |
| Profit before tax | 440 | 256 | 478 | 804 | 818 | 164 | 506 | 572 | 614 | 161 | 144 | 186 |
| Tax | 70.6 | 43.6 | 91.3 | 135 | 142 | 31.3 | 99.9 | 91.6 | 95.8 | 20.7 | -89.2 | 63.4 |
| Net profit | 369 | 213 | 386 | 669 | 677 | 132 | 406 | 480 | 518 | 151 | 269 | 207 |
| Profit to shareholders | 369 | 213 | 386 | 669 | 677 | 133 | 407 | 481 | 518 | 152 | 268 | 207 |
| EPS (₹) | 20.60 | 11.88 | 21.56 | 37.32 | 37.81 | 7.43 | 22.70 | 26.84 | 28.94 | 8.46 | 14.96 | 11.53 |
Profit & loss
Results for each year
8 financial years (April to March), consolidated, ₹ crore.
Sales, operating profit and net profit
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY26
Revenue · YoY (vs a year ago)
—-8.6%+7.2%-5.2%+39%+48%+11%-7.9%
Net profit · YoY (vs a year ago)
—-28%-4.3%-61%+321%+94%+36%-25%
RevenueOperating profitNet profitLine = trend
| ₹ Cr | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,095 | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 | 4,430 | 4,078 |
| Other income | 130 | 107 | 104 | 99.0 | 105 | 128 | 355 | 298 |
| Total expenses | 1,400 | 1,454 | 1,576 | 1,842 | 1,950 | 2,453 | 2,493 | 2,885 |
| Employee cost | 356 | 375 | 415 | 445 | 487 | 525 | 595 | 687 |
| Operating profit | 795 | 583 | 606 | 264 | 936 | 1,751 | 2,196 | 1,437 |
| OPM % | 37.9% | 30.4% | 29.5% | 13.5% | 34.6% | 43.8% | 49.6% | 35.2% |
| Finance cost | 19.3 | 21.5 | 13.3 | 17.7 | 14.5 | 19.2 | 23.9 | 36.7 |
| Depreciation | 81.0 | 99.8 | 117 | 143 | 164 | 187 | 235 | 207 |
| Profit before tax | 825 | 569 | 580 | 202 | 862 | 1,674 | 2,291 | 1,491 |
| Tax | 182 | 111 | 137 | 32.2 | 147 | 285 | 408 | 119 |
| Tax rate % | 22.1% | 19.4% | 23.7% | 15.9% | 17.0% | 17.0% | 17.8% | 8.0% |
| Net profit | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,883 | 1,419 |
| Profit to shareholders | 644 | 461 | 441 | 170 | 715 | 1,388 | 1,885 | 1,419 |
| Net margin % | 30.8% | 24.1% | 21.5% | 8.7% | 26.4% | 34.7% | 42.6% | 34.8% |
| EPS (₹) | 34.87 | 25.26 | 24.16 | 9.32 | 39.18 | 77.34 | 105.26 | 79.20 |
Balance sheet
Assets and debt
At each year end (and the latest half year), ₹ crore.
Equity, debt and assets
Mar 23
Mar 24
Mar 25
Mar 26
Shareholders' equity · YoY (vs a year ago)
—+20%+30%+21%
Shareholders' equityBorrowingsCashLine = trend
| ₹ Cr | Mar 23 | Mar 24 | Mar 25 | Mar 26 |
|---|---|---|---|---|
| Shareholders' equity | 4,874 | 5,853 | 7,607 | 9,221 |
| Long-term borrowings | 0.0 | 0.0 | 0.0 | 100 |
| Short-term borrowings | 165 | 363 | 273 | 606 |
| Total borrowings | 165 | 363 | 273 | 706 |
| Current liabilities | 683 | 973 | 944 | 1,681 |
| Fixed assets (PPE) | 2,239 | 2,298 | 2,432 | 2,545 |
| Inventories | 743 | 701 | 766 | 909 |
| Trade receivables | 856 | 1,189 | 1,247 | 881 |
| Cash & equivalents | 132 | 70.4 | 120 | 199 |
| Current assets | 3,000 | 4,024 | 5,270 | 5,052 |
| Total assets | 5,657 | 6,906 | 8,631 | 11,074 |
| Debt / equity | 0.03 | 0.06 | 0.04 | 0.08 |
Cash flow
Cash coming in and going out
For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.
Operating, investing and financing cash
FY22
FY23
FY24
FY25
FY26
Operations · YoY (vs a year ago)
—+1,726%+43%+40%+4.2%
OperationsInvestingFinancingLine = trend
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 46.5 | 849 | 1,212 | 1,697 | 1,768 |
| Cash from investing | -5.3 | -477 | -1,033 | -1,415 | -2,143 |
| Cash from financing | 34.8 | -363 | -247 | -211 | 298 |
| Spent on fixed assets | -233 | -146 | -339 | -401 | -388 |
| Free cash flow | -186 | 703 | 872 | 1,296 | 1,380 |
| Net cash flow | 76.0 | 9.0 | -68.0 | 71.6 | -77.1 |
Shareholding
Who holds the shares
Promoter and public holding at each quarter end, as filed with NSE.
Holding over time
Promoter & groupPublic
Latest (23 Oct 2026)
46.2%promoter
- Promoter & group
- 46.22%
- Public (FIIs, mutual funds, retail…)
- 53.78%
- Promoter change, last quarter
- -3.17 pts
Dividends & news
Latest dividends and announcements
Dividends & corporate actions
- Rights 2:21 @ Premium Rs 748/-
- Interim Dividend - Rs 1.50 Per Share
- Interim Dividend - Rs 1.50 Per Share
- Interim Dividend - Rs 1.50 Per Share
- Interim Dividend - Rs 2 Per Share
- Interim Dividend - Rs 1.50 Per Share
- Interim Dividend - Rs 1.50 Per Share
- Annual General Meeting
Board meetings
- the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Dividend.
- the financial results for the period ended September 30, 2026 and dividend
- Fund raising.
- to consider, discuss and decide various matters in connection with the Rights Issue, including the specific terms of the Rights Issue, such as the de…
- Fund raising.
Filings with NSE
- Analysts/Institutional Investor Meet/Con. Call Updates
- Copy of Newspaper Publication
- Allotment of Securities
- Committee Meeting Updates
- Trading Window
- General Updates
- Press Release
Latest news
Natco Pharma Ltd. Rights Issue: Price, Record Date, Entitlement Ratio And Key DetailsICICI Direct · 9 Oct, 12:30 pmNatco Pharma approves ₹1,279 crore rights issue - Check dates, price, entitlement ratio and more - CNBC TV18LinkedIn · 25 Sep, 12:30 pmNatco Pharma Plans ₹1,279 Cr Rights Issue at ₹750HDFC Sky · 25 Sep, 12:30 pmNatco Pharma’s board approves rights issue worth ₹1,279 crore; check issue price, record date and moreUpstox · 25 Sep, 12:30 pmNatco Pharma Q1 revenue tumbles 44% to ₹735 cr; plans ₹2000-cr QIP to fuel acquisitionspharma.economictimes.indiatimes.com · 17 Aug, 12:30 pmNatco Pharma stock price slips 20% in 2 days; should you buy, sell or hold?Business Standard · 1 Jun, 12:30 pmNatco Pharma shares fall 12% as firm reports 34% drop in Q4 net profit at Rs 268 croreMoneycontrol.com · 29 May, 12:30 pmNatco Pharma Shares Rise on Rs 2,500 Crore Expansion StrategyEquitypandit · 9 Jul, 12:30 pmAbout
About Natco Pharma Limited
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs at affordable prices.
From Wikipedia (CC BY-SA 4.0).
Company details
- Company name
- Natco Pharma Limited
- NSE symbol
- NATCOPHARM
- BSE scrip code
- 524816
- ISIN
- INE987B01026
- Listed on
- NSE, BSE
- Series
- EQ (normal equity)
- Listed on NSE since
- 27 Dec 1995
- Face value
- ₹2 per share
- Market lot
- 1 share
- Shares issued
- 17.90 crore
- Index
- NIFTY 500
- Sector (NSE)
- Healthcare
- Industry
- Pharmaceuticals: Major
- Chair
- Venkaiah Chowdary Nannapaneni
- Headquarters
- Hyderabad
- Registered address
- NATCO HOUSE ROAD NO 2 BANJARA HILLS HYDERABAD
- Founded
- 1981
- Employees
- 5,060
- Financial year
- April to March
- Results basis
- Consolidated
- Website
- natcopharma.co.in
Peers
Other Healthcare stocks
-
DIVISLABDivi's Laboratories
₹11,485.00
+1.04%
-
ALKEMAlkem Laboratories
₹5,302.00
-2.68%
-
GRANULESGranules India
₹840.50
+5.16%
-
SUNPHARMASun Pharmaceutical Industries
₹1,885.00
-0.91%
-
LAURUSLABSLaurus Labs
₹2,400.00
-1.19%
-
AUROPHARMAAurobindo Pharma
₹1,807.20
-1.11%
-
ACUTAASAcutaas Chemicals
₹3,996.10
+2.02%
-
APOLLOHOSPApollo Hospitals Enterprise
₹8,515.00
-1.03%
Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.